F16.94 Hallucinogen use, unspecified with hallucinogen-induced mood disorder

Name of the Condition

• Hallucinogen Use, Unspecified with Hallucinogen-Induced Mood Disorder
• Medical Term: ICD-10-CM F16.94

Summary

Hallucinogen use, unspecified with hallucinogen-induced mood disorder refers to the use of hallucinogenic substances associated with a mood disorder directly caused by the substance. This code is applied when clinical documentation confirms hallucinogen exposure and a mood disorder (e.g., depression, mania) that is attributed to the substance, without specifying the pattern of use or other complications. It is used for cases where the mood disorder is the primary focus, and the use pattern is not detailed.

Causes

Hallucinogen use, unspecified with hallucinogen-induced mood disorder typically involves substances that alter perception, mood, or cognitive function, such as LSD, psilocybin, or mescaline. The mood disorder arises from the direct physiological or psychological effects of the substance, rather than a pre-existing condition. Documentation indicates the substance is the cause, but the pattern of use (e.g., abuse, dependence) is not specified.

Risk Factors

• Recreational or experimental use of hallucinogens
• Pre-existing mental health conditions
• Genetic predisposition to substance-induced mood disorders
• Social or peer pressure to use drugs
• Access to hallucinogenic substances

Symptoms

• Altered sensory perceptions (e.g., visual or auditory hallucinations)
• Distorted sense of reality or time
• Mood changes, including depression, mania, or anxiety
• Impaired judgment or decision-making
• Sleep disturbances
• Changes in appetite or energy levels

Diagnosis

Diagnosis requires clinical documentation of hallucinogen use and a mood disorder that is directly attributed to the substance. The provider must confirm the temporal relationship between use and symptoms, ruling out other causes (e.g., primary mood disorders). No specific pattern of use (e.g., abuse, dependence) is required for this code, but the mood disorder must be linked to the hallucinogen exposure.

Treatment Options

Treatment focuses on managing the mood disorder and addressing substance use. Interventions may include:

• Pharmacotherapy for mood symptoms (e.g., antidepressants or mood stabilizers)
• Psychotherapy (e.g., cognitive-behavioral therapy)
• Substance use counseling or education
• Supportive care for acute symptoms

Prognosis and Follow-Up

Prognosis depends on the severity of the mood disorder and the individual’s response to treatment. Follow-up is recommended to monitor mood symptoms, substance use patterns, and treatment adherence. Long-term management may be necessary if the mood disorder persists or recurs.

Complications

• Worsening of mood symptoms (e.g., suicidal ideation)
• Increased risk of substance use disorders
• Impaired social or occupational functioning
• Co-occurring mental health conditions (e.g., anxiety, psychosis)

Lifestyle & Prevention

• Avoiding hallucinogenic substances to prevent recurrence
• Engaging in stress-reduction techniques (e.g., exercise, mindfulness)
• Building a support network (e.g., family, support groups)
• Maintaining regular mental health check-ins

When to Seek Professional Help

Seek help if mood symptoms (e.g., persistent sadness, mania, or anxiety) interfere with daily life, or if substance use continues despite negative consequences. Immediate care is needed for severe symptoms (e.g., suicidal thoughts or self-harm).

Tips for Medical Coders

Use F16.94 when clinical documentation specifies hallucinogen use and a hallucinogen-induced mood disorder, without detailing the pattern of use. Ensure the mood disorder is directly attributed to the substance (not a pre-existing condition) and that no other complications (e.g., intoxication, withdrawal) are documented. Verify that the code aligns with the provider’s diagnostic statement and supporting documentation.